Table 2

DAPSA28 LDA (≤14) or remission (≤4) at 6 months with OR and presented by treatment course: results of multivariable logistic regression analyses

First courseAdalimumabAbataceptApremilastIxekizumabSecukinumabTofacitinibUstekinumab
LDA, n1880 (1838–1933)/31716 (4–9)/25208 (183–229)/50019 (15–24)/41143 (132–158)/26427 (20–32)/4759 (50–68)/128
OR crudeReference–0.49 (0.38–0.63)–0.81 (0.59–1.11)–0.59 (0.37–0.96)
OR age/sex-adjustedReference–0.50 (0.39–0.65)–0.82 (0.60–1.14)–0.59 (0.36–0.96)
OR fully adjustedReference–0.49 (0.37–0.66)–0.85 (0.60–1.19)–0.58 (0.35–0.97)
OR IPTW0.52 (0.39–0.70)0.89 (0.67–1.17)0.62 (0.42–0.92)
Remission, n792 (736–829)/31711 (0–2)/2558 (41–75)/5006 (1–11)/4146 (40–51)/26415 (11–17)/4716 (10–22)/128
OR crudeReference–0.38 (0.24–0.58)–0.63 (0.43–0.91)–0.42 (0.19–0.92)
OR age/sex-adjustedReference–0.41 (0.26–0.64)–0.65 (0.44–0.95)–0.42 (0.19–0.92)
OR fully adjustedReference–0.43 (0.25–0.72)–0.67 (0.45–1.02)–0.41 (0.18–0.94)
OR IPTW0.44 (0.26–0.74)0.70 (0.50–0.98)0.55 (0.29–1.05)
Second/third course
LDA, n1001 (956–1022)/207137 (32–43)/13163 (51–77)/27251 (44–57)/156420 (401–441)/96373 (63–85)/185100 (87–111)/295
OR crudeReference0.41 (0.26–0.65)0.32 (0.21–0.48)0.52 (0.33–0.81)0.83 (0.68–1.02)0.69 (0.46–1.03)0.54 (0.39–0.77)
OR age/sex-adjustedReference0.42 (0.26–0.66)0.34 (0.22–0.51)0.52 (0.33–0.82)0.83 (0.68–1.02)0.73 (0.49–1.09)0.55 (0.39–0.78)
OR fully adjustedReference0.48 (0.29–0.77)0.35 (0.22–0.54)0.54 (0.33–0.87)0.88 (0.70–1.11)0.72 (0.46–1.12)0.64 (0.45–0.92)
OR IPTW0.48 (0.30–0.79)0.35 (0.23–0.55)0.57 (0.33–0.99)0.90 (0.73–1.11)0.79 (0.49–1.26)0.64 (0.44–0.94)
Remission, n325 (304–347)/20717 (4–12)/13110 (4–16)/27211 (6–22)/156110 (100–124)/96320 (15–26)/18523 (16–31)/295
OR crudeReference0.28 (0.09–0.83)0.20 (0.07–0.54)0.41 (0.15–1.06)0.68 (0.51–0.90)0.61 (0.33–1.13)0.41 (0.22–0.77)
OR age/sex-adjustedReference0.29 (0.10–0.88)0.21 (0.08–0.60)0.40 (0.15–1.07)0.67 (0.50–0.91)0.71 (0.38–1.31)0.42 (0.22–0.79)
OR fully adjustedReference0.38 (0.12–1.18)0.23 (0.08–0.65)0.43 (0.16–1.18)0.75 (0.54–1.03)0.73 (0.38–1.41)0.54 (0.28–1.05)
OR IPTW0.35 (0.13–1.01)0.21 (0.07–0.66)0.80 (0.34–1.87)0.76 (0.55–1.04)0.73 (0.36–1.48)0.55 (0.28–1.07)
Fourth course or more
LDA, n149 (140–160)/39718 (14–26)/14037 (31–43)/17737 (28–45)/161234 (221–248)/71786 (79–95)/27069 (59–79)/277
OR crudeReference0.25 (0.13–0.47)0.43 (0.27–0.68)0.50 (0.30–0.83)0.80 (0.60–1.07)0.77 (0.54–1.11)0.55 (0.37–0.82)
OR age/sex-adjustedReference0.26 (0.13–0.50)0.43 (0.27–0.69)0.52 (0.31–0.86)0.82 (0.61–1.09)0.80 (0.56–1.15)0.56 (0.38–0.84)
OR fully adjustedReference0.27 (0.14–0.52)0.41 (0.25–0.68)0.55 (0.32–0.96)0.85 (0.63–1.16)0.89 (0.60–1.32)0.52 (0.33–0.81)
OR IPTW0.27 (0.11–0.65)0.38 (0.26–0.57)0.46 (0.13–1.64)0.83 (0.62–1.11)0.99 (0.58–1.69)0.57 (0.36–0.89)
Remission, n35 (28–41)/3973 (1–5)/1408 (5–13)/1775 (2–9)/16142 (35–49)/71713 (9–18)/27016 (11–21)/277
OR crudeReference0.18 (0.03–1.08)0.49 (0.18–1.38)0.33 (0.08–1.31)0.64 (0.36–1.14)0.51 (0.23–1.13)0.61 (0.29–1.31)
OR age/sex-adjustedReference0.22 (0.04–1.31)0.54 (0.19–1.52)0.37 (0.09–1.49)0.69 (0.38–1.23)0.59 (0.26–1.33)0.66 (0.30–1.41)
OR fully adjustedReference0.23 (0.04–1.43)0.55 (0.19–1.57)0.44 (0.10–1.91)0.79 (0.41–1.52)0.72 (0.29–1.76)0.53 (0.23–1.19)
OR IPTW0.14 (0.00–7.07)0.47 (0.15–1.45)0.39 (0.02–6.96)0.80 (0.43–1.48)0.37 (0.11–1.26)0.59 (0.21–1.62)

  • Results are shown for patients with more than 6 months of follow-up. ORs are not presented for exposure groups of <100 patients (as indicated by –).

  • The fully adjusted model included age (and the quadratic term), sex, disease duration, csDMARD use, C reactive protein, patient global score, treatment start year, comorbidity score and previous infection.

  • Results including imputation of missing data. Numbers in parentheses for remission and LDA are minimum–maximum across the imputations, with the denominator showing all patients in the group.

  • csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAPSA28, Disease Activity index for PSoriatic Arthritis based on 28-joint evaluation; IPTW, inverse probability of treatment-weighted; LDA, low disease activity.